Avexa and Novasep Today Announce Signing of Manufacturing Agreement for ATC |
(Archive News Story - Products mentioned in this Archive News Story may or may not be available from the manufacturer.)
Novasep, Inc.
23 Creek Circle
Boothwyn, PA, 19061
USA
Press release date: February 15, 2007
POMPEY, France, February 15: Avexa (ASX:AVX) and Novasep today announced the signing of a manufacturing agreement for the production of apricitabine (ATC), Avexa's novel nucleoside reverse transcriptase inhibitor (NRTI) which is in clinical development for the treatment of HIV infection. The agreement covers the continued production, process optimisation, and further scale-up of the active pharmaceutical ingredient (API) of ATC based upon the Varicol(R) continuous chromatography system for use in Phase III clinical trials and in preparation for the commercial launch of the product.
"Novasep is a well established company with extensive experience in the chemical processes required for ATC production," said Dr Julian Chick, CEO of Avexa. "We are delighted to be working with Novasep on the production and supply of ATC API for our Phase III programme. The signing of this agreement signals yet another step forward in the progression of apricitabine towards the market."
Avexa is a Melbourne-based biotechnology company with a focus on research and development of drugs for the treatment of infectious diseases, in particular diseases which have a significant unmet medical need.
Avexa has dedicated resources and funding for key projects including antiviral drugs for HIV/Aids and an antibiotic alternative for antibiotic-resistant bacterial infections. The Company's lead programme is apricitabine which is currently in Phase IIb clinical trials. Recruitment for Phase IIb was completed at the end of 2006 and the results are due in the first quarter of 2007. For more information please visit Avexa website www.avexa.com.au or contact: Dr. Julian Chick Chief Executive Officer +61-(03)-9208-4300 Mr. Rod North Bourse Communications +61-(03)-9510-8309
Novasep Synthesis provides R&D and exclusive synthesis, from lab to industrial scale, with special expertise in hazardous chemistry, chiral technologies, Highly Potent APIs and Early Stage Services. Novasep Synthesis includes two business units: exclusive synthesis and proprietary products.
Groupe Novasep covers the special needs of the pharmaceutical, food, cosmetics, agrochemicals, and specialty chemicals industries. It combines chemical synthesis and chemical engineering expertise in order to develop new technologies. The group operates through two divisions: Novasep Synthesis and Novasep Process focusing on the synthesis and process of intermediates, advanced intermediates and APIs. For more information please visit Novasep website www.novasep.com or contact: Jean-Marc Le Rudulier Marketing & Communication Director Groupe Novasep Tel : +33-(0)3-83-49-71-46 About Groupe Novasep
|
|
|
|
|
|
|
|
|
|
|
| 
